Birmingham, Alabama – A potential treatment of preeclampsia now on its way, advanced drug trial begins.
The Role of UAB
The University of Alabama at Birmingham (UAB) plays a significant role in the entire discovery of treatment. It has conducted an advanced drug trial to find a potential treatment for the deadly pregnancy complication called preeclampsia. Pregnant women who have this condition need an urgent care since it’s fatal, and could significantly affect the unborn child. The condition is known to cause infant mortality and pre-term births. The very first in the United States, UAB has enrolled the first patient in a Phase III clinical trial to hunt for possible solutions.
Deadly Preeclampsia
Initially, the fatal condition affects a minimal number of pregnancies, recorded between 5 and 8 percent. However, its prevalence is growing, and cases have increased to 25 percent. The cause of preeclampsia is still unknown, even an urgent care clinic failed to learn its cause. The condition is associated with an abnormal development of blood vessels from the mother’s uterus to the placenta. This results to a decreased flow of oxygen and nutrients to the baby, which are essential throughout the pregnancy. The condition poses an increased risk of prematurity or abnormal fetal growth. Urgent care clinics and tests indicated that women with such condition showed swollen blood vessels, which result in kidney problems, stroke, high blood pressure, and further complications.
Drug Trial
The search for potential treatment of preeclampsia involved antithrombin recombinant, also known as ATryn, and manufactured by rEVO Biologics Inc. The drug was administered between the 24th and 28th week of the pregnancy. This process was referred to as the PRESERVE-1 trial. It will assess if the drug will prolong the pregnancy during the early onset of the condition. It will also identify whether the drug can reduce the rates of perinatal disability and perinatal mortality.
Potential Treatment
Doctor Alan Tita, is the lead investigator of the study and an Obstetrics and Gynecology professor at the UAB. She emphasized that the ultimate, potential treatment of preeclampsia is to deliver the baby safely. This is the only thing they can offer to pregnant women with such condition, a sort of an urgent care near me relief to those suffering from preeclampsia. Tita said that the earliest occurrence of the disorder during pregnancy could pose more serious risks to the mother and the baby. However, the target group in the clinical study indicates a more substantial, advanced, and potential treatment of preeclampsia, implying improved outcomes both for the mother and the unborn child.
